Nav: Home

Down's neonatal screening contract renewed

May 09, 2016

Public Health England (PHE) has renewed its contract with Plymouth University Peninsula Schools of Medicine and Dentistry (PUPSMD) to provide the Down's syndrome screening Quality Assurance Support Service (DQASS) for its Down's, Edwards' and Patau's syndromes antenatal screening programme in England.

The service has been run by staff in the Biostatistics, Bioinformatics and Biomarkers (BBB) group at PUPSMD since its inception in 2006, initially with the Department of Health and then Public Health England. The DQASS team, headed by lead statistician Dr Amy Baker, will be celebrating 10 years in operation later this year and will be marking the milestone with a research paper documenting the progress and developments of the screening programme and DQASS over the last decade.

DQASS provides a confidential and independent audit of laboratory and ultrasound data. The service is also provided to NHS Scotland and NHS Wales under the same contract. The primary aim is to improve the risk calculations of Down's, Edwards' and Patau's syndromes by supporting and assisting local screening programmes. This is achieved by monitoring practice and, where necessary, providing advice and support to make improvements in collaboration with the NHS Foetal Anomaly Screening Programme (FASP).

All laboratories which contribute to the NHS screening programmes for the three chromosomal abnormalities must submit data to DQASS on a six-monthly cycle for analysis. Currently the DQASS team provides analyses and feedback to 25 laboratories, approximately 200 NHS hospitals and over 3,000 individual sonographers across the UK. Feedback is also provided to a variety of stakeholders.

In addition to the risk calculations for Down's syndrome, the new contract will provide further developments in relation to the combined risk calculations of Edwards' and Patau's syndromes. These will be incorporated into current reporting outputs. The team will also work with PHE and NHS FASP to consider future changes and progressions to foetal anomaly screening, such as work to support the introduction of non-invasive prenatal testing.

The BBB group from PUPSMD is led by Siobhan Creanor, Associate Professor in Clinical Trials and Medical Statistics and Director of the Plymouth University Peninsula Clinical Trials Unit, which is registered by the UK Clinical Research Collaboration (UKCRC). She said: "We are delighted to have retained this contract with PHE. Accurate identification of these three foetal anomalies in the womb is very important for both the child and the parents, which is why we need to ensure that screening programmes are performing as they should. We are also excited about the prospect of working with PHE to improve services and introduce new techniques, such as non-invasive prenatal testing."

University of Plymouth

Related Clinical Trials Articles:

Giving children a voice in clinical trials
Children as young as 8 years old with incurable cancer can reliably characterize the impact an experimental therapy has on their symptoms and quality of life -- even at the earliest stages of drug development -- making self-reported patient outcomes a potential new clinical trial endpoint.
Better health for women involved in clinical trials
Women who participate in obstetric and gynecology clinical trials experience improved health outcomes compared to those who are not involved in trials, according to research by Queen Mary University of London.
Final artificial pancreas clinical trials now open
Clinical trials are now enrolling to provide the final tests for a University of Virginia-developed artificial pancreas to automatically monitor and regulate blood-sugar levels in people with type 1 diabetes.
Why the bar needs to be raised for human clinical trials
Standards for authorizing first-time trials of drugs in humans are lax, and should be strengthened in several ways, McGill University researchers argue in a paper published today in Nature.
New drug formulary will help expedite use of agents in clinical trials
The National Cancer Institute (NCI) today launched a new drug formulary (the 'NCI Formulary') that will enable investigators at NCI-designated Cancer Centers to have quicker access to approved and investigational agents for use in preclinical studies and cancer clinical trials.
More Clinical Trials News and Clinical Trials Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#534 Bacteria are Coming for Your OJ
What makes breakfast, breakfast? Well, according to every movie and TV show we've ever seen, a big glass of orange juice is basically required. But our morning grapefruit might be in danger. Why? Citrus greening, a bacteria carried by a bug, has infected 90% of the citrus groves in Florida. It's coming for your OJ. We'll talk with University of Maryland plant virologist Anne Simon about ways to stop the citrus killer, and with science writer and journalist Maryn McKenna about why throwing antibiotics at the problem is probably not the solution. Related links: A Review of the Citrus Greening...